View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar Neurológiai Klinika Budapest Balassa u. 6. 1083
Open access

Cross Mark

A nem valvularis eredetű pitvarfibrilláció az embóliás agyi infarktusok egyik legfontosabb kockázati tényezője. Kezelésében a K-vitamin-antagonisták mellett az elmúlt években megjelenő új típusú orális antikoagulánsok egyre nagyobb teret kapnak. A dabigatran, a rivaroxaban és az apixaban a klinikai gyakorlatban elérhető új típusú orális antikoagulánsok. Az összefoglaló ezek alkalmazásának irányelveit, tulajdonságaikat tekinti át ischaemiás stroke szekunder prevenciójában, hipotetikus esetismertetés kapcsán felmerülő kérdéseket tárgyalva. Orv. Hetil., 2014, 155(42), 1655–1660.

  • Palacio, S., Hart, R. G.: Neurologic manifestations of cardiogenic embolism: an update. Neurol. Clin., 2002, 20(1), 179–193.

  • Ferro, J. M.: Cardioembolic stroke: an update. Lancet Neurol., 2003, 2(3), 177–188.

  • Kittner, S. J., Sharkness, C. M., Sloan, M. A., et al.: Infarcts with a cardiac source of embolism in the NINDS Stroke Data Bank: neurologic examination. Neurology, 1992, 42(2), 299–302.

  • Gács, G., Fox, A. J., Barnett, H. J., et al.: CT visualization of intracranial arterial thromboembolism. Stroke, 1983, 14(5), 756–762.

  • Wolf, P. A., Abbott, R. D., Kannel, W. B.: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke, 1991, 22(8), 983–988.

  • Tomcsányi, J., Bózsik, B., Rokszin, G., et al.: The prevalence of atrial fibrillation in Hungary. [A pitvarfibrilláció prevalenciája Magyarországon.] Orv. Hetil., 2012, 153(9), 339–342. [Hungarian]

  • Gage, B. F., Waterman, A. D., Shannon, W., et al.: Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA, 2001, 285(22), 2864–2870.

  • Hohnloser, S. H., Pajitnev, D., Pogue, J., et al.: Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J. Am. Coll. Cardiol., 2007, 50(22), 2156–2161.

  • Camm, A. J., Lip, G. Y., De Caterina, R., et al.: 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation – developed with the special contribution of the European Heart Rhythm Association. Europace, 2012, 14(10), 1385–1413.

  • Kernan, W. N., Ovbiagele, B., Black, H. R., et al.: Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2014, 45(7), 2160–2236.

  • Saposnik, G., Gladstone, D., Raptis, R., et al.: Atrial fibrillation in ischemic stroke. Predicting response to thrombolysis and clinical outcomes. Stroke, 2013, 44(1), 99–104.

  • Gladstone, D. J., Bui, E., Fang, J., et al.: Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke, 2009, 40(1), 235–240.

  • Hart, R. G., Pearce, L. A., Aguilar, M. I.: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med., 2007, 146(12), 857–867.

  • Weitz, J. I.: Meeting the unmet needs in anticoagulant therapy. Eur. J. Haematol., 2010, (Suppl. 72), 1–28.

  • Gallagher, A. M., Setakis, E., Plumb, J. M., et al.: Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb. Haemost., 2011, 106(5), 968–977.

  • Gallagher, A. M., Rietbrock, S., Plumb, J., et al.: Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J. Thromb. Haemost., 2008, 6(9), 1500–1506.

  • Glader, E. L., Sjölander, M., Eriksson, M., et al.: Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke, 2010, 41(2), 397–401.

  • Nieuwlaat, R., Capucci, A., Lip, G. Y., et al.: Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur. Heart. J., 2006, 27(24), 3018–3026.

  • Wallentin, L., Lopes, R. D., Hanna, M., et al.: Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation, 2013, 127(22), 2166–2176.

  • Cairns, J. A.: Which oral anticoagulant for which atrial fibrillation patient: recent clinical trials and evidence-based choices. Can. J. Cardiol., 2013, 29(10), 1165–1172.

  • Connolly, S. J., Ezekowitz, M. D., Yusuf, S., et al.: Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med., 2009, 361(12), 1139–1151.

  • Patel, M. R,, Mahaffey, K. W., Garg, J., et al.: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med., 2011, 365(10), 883–891.

  • Granger, C. B., Alexander, J. H., McMurray, J. J., et al.: Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2011, 365(11), 981–992.

  • Cohen, D.: Concerns over data in key dabigatran trial. Br. Med. J., 2014, 349, g4747.

  • Capranzano, P., Miccichè, E., D’Urso, L., et al.: Personalizing oral anticoagulant treatment in patients with atrial fibrillation. Expert Rev. Cardiovasc. Ther., 2013, 11(8), 959–973.

  • Connolly, S. J., Pogue, J., Hart, R. G., et al.: Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ACTIVE Investigators, N. Engl. J. Med., 2009, 360(20), 2066–2078.

  • Culebras, A., Messé, S. R., Chaturvedi, S., et al.: Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation. Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 2014, 82(8), 716–724.

  • Connolly, S. J., Eikelboom, J., Joyner, C., et al.: Apixaban in patients with atrial fibrillation. N. Engl. J. Med., 2011, 364(9), 806–817.

  • Coppens, M., Synhorst, D., Eikelboom, J. W., et al.: Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial. Eur. Heart J., 2014, 35(28), 1856–1863.

  • CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet, 1997, 349(9066), 1641–1649.

  • The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet, 1997, 349(9065), 1569–1581.

  • Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute StrokeTreatment (TOAST) Investigators. JAMA, 1998, 279(16), 1265–1272.

  • Jauch, E. C., Saver, J. L., Adams, H. P. Jr., et al.: Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2013, 44(3), 870–947.

  • Mandzia, J. L., Hill, M. D.: Acute stroke management in patients with known or suspected atrial fibrillation. Can. J. Cardiol., 2013, 29(7 Suppl), S45–S53.

  • Immediate anticoagulation of embolic stroke: brain hemorrhage and management options. Cerebral Embolism Study Group. Stroke, 1984, 15(5), 779–789.

  • Cardioembolic stroke, early anticoagulation, and brain hemorrhage. Cerebral Embolism Study Group. Arch. Intern. Med., 1987, 147(4), 636–640.

  • Rosanio, S., Keylani, A. M., D’Agostino, D. C., et al.: Pharmacology, benefits, unaddressed questions and pragmatic issues of newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm. Int. J. Cardiol., 2014, 174(3), 471–483.

  • Lip, G. Y., Larsen, T. B., Skjøth, F.: Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J. Am. Coll. Cardiol., 2012, 60(8), 738–746.

  • Mantha, S., Ansell, J.: An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb. Haemost., 2012, 108(3), 476–484.

  • Harenberg, J., Marx, S., Diener, H. C., et al.: Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network metaanalysis. Int. Angiol., 2012, 31(4), 330–339.

  • Baker, W. L., Phung, O. J.: Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation. Circ. Cardiovasc. Qual. Outcomes., 2012, 5(5), 711–719.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 14 12 4
PDF Downloads 23 22 5